Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WiNK: oNKord in AML with MRD
NCT04632316Phase 2Unknown
- Sponsor
- Glycostem Therapeutics
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Cell Therapies
- Countries
- 5
01
Overview
A Phase 2 trial of oNKord in acute myeloid leukemia (AML), sponsored by Glycostem Therapeutics. Status: unknown.
02
Drugs
oNKord
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04632316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632316.